Genentech ordered to halt Rituxan trials
An arbitrator has ruled that Genentech must halt several trials until Biogen Idec says they can move forward. In 2006, the two companies, filed for arbitration to settle whether Genentech could develop follow-on drugs to the cancer and rheumatoid arthritis drug Rituxan, without Biogen's approval. The arbitrator ruled that three of the trials must be halted, although a Phase III trial for the arthritis biologic ocrelizumab can continue. [more...]
|
|
|
